Project description
Intelligent RNA-based delivery of new information into live cells
The EU-funded DESTINATION project aims to create a first-generation RNA-based delivery platform (RNano) for effective delivery of information (mRNA) into cells in vivo. Addressing this challenging goal requires a novel, biocompatible and scalable system to protect the deliverable mRNA from degradation in blood, escape the immune response, and provide high selectivity in cell targeting. The consortium will use AI/machine learning to generate a library of programmable RNano scaffolds for packaged mRNA and RNA aptamers for laser-specific internalisation of RNanos into cells. DESTINATION success could enable novel functions such as the production of a cell's own medicine by replacing the faulty mRNA or engineering cells to fight genetic disorders and cancer.
Objective
By combining the interdisciplinary fields of AI/machine learning with RNA nanotechnology, biochemistry and advanced imaging methods, DESTINATION aims to create a first-generation RNA-based delivery platform (RNano) for effective delivery of information such as mRNA into cells in vivo. mRNA translate the information encoded in a cell’s DNA into the proteins that are essential for diverse cell function and can be deficient in disease. Administering mRNA into a cell could enable diverse novel functions such as production of its own medicine by replacing the faulty mRNA or engineering cells to fight diseases from genetic disorders and cancer to infectious diseases. However, the ability to deliver mRNA to specific cells in a targeted organ remains an unmet challenge that limits its clinical and commercial potential. Addressing this challenge requires a novel, biocompatible and scalable system capable of (1) protecting the mRNA from degradation in blood; (2) evading the immune response; (3) and providing high selectivity for targeted cells. DESTINATION will generate an intelligent library of (a) programmable RNano scaffolds for attachment of packaged mRNA and (b) RNA aptamers for laser-specific internalization of RNanos into cells. Promising candidates will be tested in vitro, with lead candidates progressed to novel animal models. Ultra high-resolution imaging will allow for the evaluation of the technology, with an iterative R&D approach aimed at demonstrating 3breakthrough preclinical proof-of-concepts incl. in the attractive field of CAR-T cancer immune-therapies. DESTINATION comprises a multi-disciplinary consortium of top academics and 3 R&D-performing SMEs acting as commercialization agents to increase DESTINATION’s impact by developing a translation strategy and communication plan focused on providing early engagement with investors, regulators, potential manufacturing and industry partners. Together, DESTINATION will strengthen EU's position in the emerging fields of RNA technology.
Fields of science
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
W12 0BZ London
United Kingdom
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.